Survey of Common Practices Among Oculofacial Surgeons in the Asia-Pacific Region: Graves’ Orbitopathy

References

• Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004;89(10):5076–5080
   PubMed Web of Science ®Google Scholar
• Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med 1993;329(20):1468–1475
   PubMed Web of Science ®Google Scholar
• Maheshwari R, Weis E. Thyroid associated orbitopathy. Ind J Ophthalmol 2012;60(2):87–93
   PubMedGoogle Scholar
• Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010;362(8):726–738
   PubMed Web of Science ®Google Scholar
• Soeters MR, van Zeijl CJ, Boelen A, et al. Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med 2011;69(7):302–308
   Web of Science ®Google Scholar
• Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab 2012;97(11):3857–3865
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158(3):273–285
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med 2009;360(10):994–1001
   PubMed Web of Science ®Google Scholar
• Bahn R. The EUGOGO consensus statement on the management of Graves’ orbitopathy: equally applicable to North American clinicians and patients. Thyroid 2008;18(3):281–282
   PubMedGoogle Scholar
• Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1998;49(1):21–28
   Google Scholar
• Ramos HE, Diehl LA, Camacho CP, et al. Management of Graves’ orbitopathy in Latin America: an international questionnaire study compared with Europe. Clin Endocrinol (Oxf) 2008;69(6):951–956
   PubMedGoogle Scholar
• Perros P, Baldeschi L, Boboridis K, et al. A questionnaire survey on the management of Graves’ orbitopathy in Europe. Eur J Endocrinol 2006;155(2):207–211
   PubMedGoogle Scholar
• Chng CL, Seah LL, Khoo DH. Ethnic differences in the clinical presentation of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab 2012;26(3):249–258
   PubMed Web of Science ®Google Scholar
• Dolman PJ. Evaluating Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 2012;26(3):229–248
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006;155(3):387–389
   Google Scholar
• Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73(8):639–644
   Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1997;47(1):9–14
   PubMed Web of Science ®Google Scholar
• EUGOGO. Clinical Activity Score (amended by EUGOGO after Mourits et al). 2012; Available from: http://www.eugogo.eu/_downloads/clincial_evaluation/CAS-GO.pdf [last accessed 26 Jul 2014]
   Google Scholar
• Werner SC. Modification of the classification of the eye changes of Graves’ disease. Am J Ophthalmol 1977;83(5):725–727
   PubMed Web of Science ®Google Scholar
• Dolman PJ, Rootman J. VISA Classification for Graves orbitopathy. Ophthal Plast Reconstr Surg 2006;22(5):319–324
   PubMed Web of Science ®Google Scholar
• Goncalves AC, Gebrim EM, Monteiro ML. Imaging studies for diagnosing Graves’ orbitopathy and dysthyroid optic neuropathy. Clinics (Sao Paulo) 2012;67(11):1327–1334
   PubMed Web of Science ®Google Scholar
• Rabinowitz MP, Carrasco JR. Update on advanced imaging options for thyroid-associated orbitopathy. Saudi J Ophthalmol 2012;26(4):385–392
   PubMedGoogle Scholar
• Kirsch E, Hammer B, von Arx G. Graves’ orbitopathy: current imaging procedures. Swiss Med Wkly 2009;139(43–44):618–623
   PubMed Web of Science ®Google Scholar
• Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995;42(1):45–50
   PubMed Web of Science ®Google Scholar
• Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011;364(20):1920–1931
   PubMed Web of Science ®Google Scholar
• Duntas LH. The evolving role of selenium in the treatment of Graves’ disease and ophthalmopathy. J Thyroid Res 2012;2012:Article ID 736161 , doi:10.1155/2012/
   Google Scholar
• Watt T, Cramon P, Bjorner JB, et al. Selenium supplementation for patients with Graves’ hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials 2013;14:119 . doi: 10.1186/745-6215-14-119
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 2005;90(9):5234–5240
   PubMed Web of Science ®Google Scholar
• Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001;24(3):152–158
   PubMed Web of Science ®Google Scholar
• Aktaran S, Akarsu E, Erbagci I, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract 2007;61(1):45–51
   PubMed Web of Science ®Google Scholar
• Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011;96(2):320–332
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86(8):3562–3567
   PubMed Web of Science ®Google Scholar
• Marino M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid 2004;14(5):403–406
   PubMed Web of Science ®Google Scholar
• Marcocci C, Watt T, Altea MA, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 2012;166(2):247–253
   PubMed Web of Science ®Google Scholar
• Verity DH, Rose GE. Acute thyroid eye disease (TED): principles of medical and surgical management. Eye (Lond) 2013;27(3):308–319
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. Autoimmunity in Graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 2011;96(8):2386–2394
   Google Scholar
• Kahaly G, Wiersinga W, eds. Management of moderately severe Graves’ orbitopathy. In Graves’ Orbitopathy: A Multidisciplinary Approach – Questions and Answers. 2nd ed. Basel: Karger, 2010, pp 120–158
   Google Scholar
• Kahaly GJ, Roesler HP, Kutzner J, et al. Radiotherapy for thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 1999;107 (Suppl 5):S201–S207
   Google Scholar
• Perry JD, Feldon SE. Rationale for radiotherapy in thyroid eye disease. Am J Ophthalmol 2009;148(6):818–819
   PubMed Web of Science ®Google Scholar
• Lee HB, Rodgers IR, Woog JJ. Evaluation and management of Graves’ orbitopathy. Otolaryngol Clin North Am 2006;39(5):923–942, vi
   Google Scholar
• Siracuse-Lee DE, Kazim M. Orbital decompression: current concepts. Curr Opin Ophthalmol 2002;13(5):310–316
   PubMedGoogle Scholar
• Tarrus-Montaner S, Lucarelli MJ, Lemke BN, Dortzbach RK. The surgical treatment of Graves' Orbitopathy: a decade of progress. Ophthalmol Clin North Am 2000;13(4):693--704
   Google Scholar
• Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000;21(2):168–199
   PubMed Web of Science ®Google Scholar